Cargando…

Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030

BACKGROUND: In 2016, the World Health Organization (WHO) and 69th World Health Assembly approved the first global health sector strategy (GHSS) on viral hepatitis with the goal to eliminate hepatitis C virus (HCV) infections worldwide. The aim is a 90% reduction of new infections and 65% reduction o...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Benedikt, Viveiros, André, Al-Zoairy, Ramona, Blach, Sarah, Brandon, Samantha, Razavi, Homie, Dorn, Livia, Finkenstedt, Armin, Effenberger, Maria, Graziadei, Ivo, Sarcletti, Mario, Tilg, Herbert, Zoller, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042769/
https://www.ncbi.nlm.nih.gov/pubmed/30001427
http://dx.doi.org/10.1371/journal.pone.0200750
_version_ 1783339216110878720
author Schaefer, Benedikt
Viveiros, André
Al-Zoairy, Ramona
Blach, Sarah
Brandon, Samantha
Razavi, Homie
Dorn, Livia
Finkenstedt, Armin
Effenberger, Maria
Graziadei, Ivo
Sarcletti, Mario
Tilg, Herbert
Zoller, Heinz
author_facet Schaefer, Benedikt
Viveiros, André
Al-Zoairy, Ramona
Blach, Sarah
Brandon, Samantha
Razavi, Homie
Dorn, Livia
Finkenstedt, Armin
Effenberger, Maria
Graziadei, Ivo
Sarcletti, Mario
Tilg, Herbert
Zoller, Heinz
author_sort Schaefer, Benedikt
collection PubMed
description BACKGROUND: In 2016, the World Health Organization (WHO) and 69th World Health Assembly approved the first global health sector strategy (GHSS) on viral hepatitis with the goal to eliminate hepatitis C virus (HCV) infections worldwide. The aim is a 90% reduction of new infections and 65% reduction of HCV-related deaths by 2030. AIM: This study reports on the epidemiology of HCV infections in the Austrian state of Tyrol (total population 750,000) and uses a predictive model to identify how the WHO strategy for elimination of HCV can be achieved. METHODS: We developed a regional disease burden model based on observed local diagnosis data from 2001 to 2016. Scenarios were developed to evaluate the impact of diagnosis and treatment on HCV-related outcomes (viremic prevalence, decompensated cirrhosis, hepatocellular carcinoma, and liver-related deaths) from 2015 through 2030. RESULTS: In the last 15 years, 1,721 patients living in Tyrol have been diagnosed with chronic HCV infection. When ageing, mortality and treatment were factored in, there were an estimated 2,043 viremic HCV infections in 2016, of which 1,136 cases had been diagnosed. A baseline model predicts a decrease of 588 HCV cases from 2015 to 2030, which would not translate into the significant reduction of infections needed to achieve WHO global health recommendations. A total of 1,843 infected individuals need to be identified and treated to achieve the WHO goals by 2030 (1,254 averted cases as compared to baseline model). Implementation of this strategy would avoid 523 new HCV infections and decreases HCV-related mortality by 73%. CONCLUSION: HCV elimination and >65% reduction of associated mortality are possible for Tyrol, but requires a significant increase in new diagnoses and treatment rate. The model presented in this study could serve as an example for other regions to reliably predict regional disease burden and estimate how WHO goals can be met in the future.
format Online
Article
Text
id pubmed-6042769
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60427692018-07-26 Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030 Schaefer, Benedikt Viveiros, André Al-Zoairy, Ramona Blach, Sarah Brandon, Samantha Razavi, Homie Dorn, Livia Finkenstedt, Armin Effenberger, Maria Graziadei, Ivo Sarcletti, Mario Tilg, Herbert Zoller, Heinz PLoS One Research Article BACKGROUND: In 2016, the World Health Organization (WHO) and 69th World Health Assembly approved the first global health sector strategy (GHSS) on viral hepatitis with the goal to eliminate hepatitis C virus (HCV) infections worldwide. The aim is a 90% reduction of new infections and 65% reduction of HCV-related deaths by 2030. AIM: This study reports on the epidemiology of HCV infections in the Austrian state of Tyrol (total population 750,000) and uses a predictive model to identify how the WHO strategy for elimination of HCV can be achieved. METHODS: We developed a regional disease burden model based on observed local diagnosis data from 2001 to 2016. Scenarios were developed to evaluate the impact of diagnosis and treatment on HCV-related outcomes (viremic prevalence, decompensated cirrhosis, hepatocellular carcinoma, and liver-related deaths) from 2015 through 2030. RESULTS: In the last 15 years, 1,721 patients living in Tyrol have been diagnosed with chronic HCV infection. When ageing, mortality and treatment were factored in, there were an estimated 2,043 viremic HCV infections in 2016, of which 1,136 cases had been diagnosed. A baseline model predicts a decrease of 588 HCV cases from 2015 to 2030, which would not translate into the significant reduction of infections needed to achieve WHO global health recommendations. A total of 1,843 infected individuals need to be identified and treated to achieve the WHO goals by 2030 (1,254 averted cases as compared to baseline model). Implementation of this strategy would avoid 523 new HCV infections and decreases HCV-related mortality by 73%. CONCLUSION: HCV elimination and >65% reduction of associated mortality are possible for Tyrol, but requires a significant increase in new diagnoses and treatment rate. The model presented in this study could serve as an example for other regions to reliably predict regional disease burden and estimate how WHO goals can be met in the future. Public Library of Science 2018-07-12 /pmc/articles/PMC6042769/ /pubmed/30001427 http://dx.doi.org/10.1371/journal.pone.0200750 Text en © 2018 Schaefer et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Schaefer, Benedikt
Viveiros, André
Al-Zoairy, Ramona
Blach, Sarah
Brandon, Samantha
Razavi, Homie
Dorn, Livia
Finkenstedt, Armin
Effenberger, Maria
Graziadei, Ivo
Sarcletti, Mario
Tilg, Herbert
Zoller, Heinz
Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
title Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
title_full Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
title_fullStr Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
title_full_unstemmed Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
title_short Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
title_sort disease burden of hepatitis c in the austrian state of tyrol – epidemiological data and model analysis to achieve elimination by 2030
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042769/
https://www.ncbi.nlm.nih.gov/pubmed/30001427
http://dx.doi.org/10.1371/journal.pone.0200750
work_keys_str_mv AT schaeferbenedikt diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT viveirosandre diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT alzoairyramona diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT blachsarah diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT brandonsamantha diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT razavihomie diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT dornlivia diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT finkenstedtarmin diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT effenbergermaria diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT graziadeiivo diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT sarclettimario diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT tilgherbert diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030
AT zollerheinz diseaseburdenofhepatitiscintheaustrianstateoftyrolepidemiologicaldataandmodelanalysistoachieveeliminationby2030